<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790192</url>
  </required_header>
  <id_info>
    <org_study_id>D1050233</org_study_id>
    <nct_id>NCT00790192</nct_id>
  </id_info>
  <brief_title>Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.</brief_title>
  <acronym>PEARL 3</acronym>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This
      clinical study is designed to test the hypothesis that lurasidone is effective, tolerable,
      and safe as compared with quetiapine XR short term among acutely psychotic patients with
      chronic schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase</measure>
    <time_frame>Week 6</time_frame>
    <description>The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment</measure>
    <time_frame>6-Weeks</time_frame>
    <description>Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 ('normal', not ill) to 7 (extremely ill).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Lurasidone 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lurasidone 160mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Lurasidone 80 mg tablets</description>
    <arm_group_label>Lurasidone 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <description>Lurasidone 4 40 mg tablets</description>
    <arm_group_label>Lurasidone 160mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine XR</intervention_name>
    <description>Quetiapine XR 600mg</description>
    <arm_group_label>Quetiapine XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo to Lurasidone or Quetiapine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent and aged between 18 and 75 years of age.

          -  Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.

          -  Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate
             and reliable contraception for duration of study.

          -  Able and agrees to remain off prior antipsychotic medication for the duration of
             study.

          -  Good physical health on the basis of medical history, physical examination, and
             laboratory screening.

          -  Willing and able to comply with the protocol, including the inpatient requirements and
             outpatient visits.

        Exclusion Criteria:

          -  Considered by the investigator to be at imminent risk of suicide or injury to self,
             others, or property.

          -  Any chronic organic disease of the CNS (other than schizophrenia).

          -  Used investigational compound within 30 days.

          -  Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence
             within the last 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>K&amp;S Professional Research Services, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacological Studies, Inc.</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Innovations, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Escondido</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apostle Clinical Trials, Inc.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Clinical Trials</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasadena Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI-Los Angeles. LLC</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Innovations, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>Sandeigo</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Highlands Ranch</city>
        <state>Colorado</state>
        <zip>80103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Fruitland Park</city>
        <state>Florida</state>
        <zip>34731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Charles Clinical Trials</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booker, J. Gary, MD. APMC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precise Clinical Research</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates</name>
      <address>
        <city>St Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Research, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Worldwide</name>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc</name>
      <address>
        <city>Holliswood</city>
        <state>New York</state>
        <zip>11423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Neurology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vijayawada Institute of Mental Health and Neurosciences</name>
      <address>
        <city>Vijayawada</city>
        <state>Andhra Pradesh</state>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.V. Medical College</name>
      <address>
        <city>Tirupati</city>
        <state>Andra Pradesh</state>
        <zip>517507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seth K M School of P G Medicine &amp; Research</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBKS Medical Institute and Research Centre</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justice K.S. Hegde Charitable Hospital</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>574160</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSS Medical College and Hospital</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanti Nursing Home</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharastra</state>
        <zip>431005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanath Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharastra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mahatma Gandhi Institute of Medical Sciences</name>
      <address>
        <city>Sewagram</city>
        <state>Maharastra</state>
        <zip>442102</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madras Medical College &amp; Government General Hospital</name>
      <address>
        <city>Chennai</city>
        <state>TamilNadu</state>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Arad</name>
      <address>
        <city>Str. Octavian Goga nr. 17</city>
        <state>Arad</state>
        <zip>310022</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie Titan &quot;Dr. Constantin Gorgos&quot;</name>
      <address>
        <city>Bdul Nicolae Grigorescu nr. 41</city>
        <state>Bucuresti</state>
        <zip>030440</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia</name>
      <address>
        <city>Sos. Berceni nr. 10-12</city>
        <state>Bucuresti</state>
        <zip>041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Judetean Arges</name>
      <address>
        <city>Str. Negru Voda nr. 53</city>
        <state>Pitesti</state>
        <zip>110069</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Neurologie si Psihiatrie Oradea</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEI of H.P. Educat. Northern SMU</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg SHI Psychiatrical Hosptial #1 n.a. Kaschenko</name>
      <address>
        <city>Gatchina</city>
        <zip>188357</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Scientific Research Institute of Psychiatry</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of RAMS Mental Health Research Center of RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Psichiatric Hospital #1</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603 155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI Samara Psychiatric Hospital</name>
      <address>
        <city>Samara</city>
        <zip>443016</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Psychiatric Hospital #2 of St. Nikolay Chudotvorets</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Psychiatric Hospital #3 of Skvortsov-Stepanov</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Psychiatric Hospital #4</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHI City Psychoneurological Dispensary #7</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg GUZ City Psychiatric Hospital #6</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kherson Regional Psychiatric Hospital</name>
      <address>
        <city>Kherson,vil.</city>
        <state>Stepanovka</state>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCH n.a.I.I.Mechnikov, Reg.Cent. of Psychosom. Pathology</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Psychiatry and Medical Psychology</name>
      <address>
        <city>Donetsk</city>
        <zip>83008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Novel Treatment and Rehabilitation of Psychotic disorders</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Psychoneurological Hospital</name>
      <address>
        <city>Kyviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Reg.St.Cl.Psych.Hosp</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reg. Psychiatric Hospital</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poltava Regional Clinical Psychiatric Hospital,</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crimean republican Clinical Psychiatric Hospital</name>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Colombia</country>
  </removed_countries>
  <results_reference>
    <citation>Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013 Apr;145(1-3):101-9. doi: 10.1016/j.schres.2013.01.009. Epub 2013 Feb 13.</citation>
    <PMID>23415311</PMID>
  </results_reference>
  <results_reference>
    <citation>Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003. Epub 2013 Aug 27.</citation>
    <PMID>24035633</PMID>
  </results_reference>
  <results_reference>
    <citation>Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014 Apr;19(2):197-205. doi: 10.1017/S1092852913000904. Epub 2013 Dec 13.</citation>
    <PMID>24330860</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>September 1, 2011</results_first_submitted>
  <results_first_submitted_qc>September 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2011</results_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>SM-13496</keyword>
  <keyword>Latuda</keyword>
  <keyword>Lurasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lurasidone 80 mg</title>
          <description>Lurasidone 80 mg tablets taken orally once a day</description>
        </group>
        <group group_id="P2">
          <title>Lurasidone 160 mg</title>
          <description>Lurasidone 160 mg (4 tablets) taken orally once a day</description>
        </group>
        <group group_id="P3">
          <title>Quetiapine XR 600mg</title>
          <description>Quetiapine XR 600 mg (4 tablets) orally taken once a day</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to &gt;= 5%.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="120"/>
                <participants group_id="P4" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lurasidone 80 mg</title>
          <description>Lurasidone 80 mg tablets taken orally once a day</description>
        </group>
        <group group_id="B2">
          <title>Lurasidone 160 mg</title>
          <description>Lurasidone 160 mg (4 tablets) taken orally once a day</description>
        </group>
        <group group_id="B3">
          <title>Quetiapine XR 600mg</title>
          <description>Quetiapine XR 600 mg (4 tablets) orally taken once a day</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to &gt;= 5%.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="122"/>
            <count group_id="B5" value="488"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="10.9"/>
                    <measurement group_id="B2" value="37.9" spread="11.3"/>
                    <measurement group_id="B3" value="37.4" spread="10.4"/>
                    <measurement group_id="B4" value="37.4" spread="10.8"/>
                    <measurement group_id="B5" value="37.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>There were two subjects, one randomized to the Quetiapine 600 mg group and one subject randomized to placebo that did not take study drug. Thus you see a discrepancy between the participant population and the overall baseline population for the two treatment groups (1 less patient in each treatment arm).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>There were two subjects, one randomized to the Quetiapine 600 mg group and one subject randomized to placebo that did not take study drug. Thus you see a discrepancy between the participant population and the overall baseline population(1 less patient in each treatment arm).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase</title>
        <description>The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.</description>
        <time_frame>Week 6</time_frame>
        <population>The primary population for the efficacy analysis was the Intent-to-Treat (ITT) population. All subjects who were randomized, received at least one dose of study medication, and have a Baseline efficacy measurement and at least one post-Baseline efficacy measurement, were in the efficacy analysis in the treatment group to which they were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone 80 mg</title>
            <description>Lurasidone 80 mg tablets taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Lurasidone 160 mg</title>
            <description>Lurasidone 160 mg (4 tablets) taken orally once a day</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine XR 600mg</title>
            <description>Quetiapine XR 600 mg (4 tablets) orally taken once a day</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to &gt;= 5%.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase</title>
          <description>The PANSS (Positive and Negative Syndrome Scale) is a 30-item scale (range 30-210) designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items. Higher scores indicate worsening.</description>
          <population>The primary population for the efficacy analysis was the Intent-to-Treat (ITT) population. All subjects who were randomized, received at least one dose of study medication, and have a Baseline efficacy measurement and at least one post-Baseline efficacy measurement, were in the efficacy analysis in the treatment group to which they were randomized.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.2" lower_limit="-25.7" upper_limit="-18.7"/>
                    <measurement group_id="O2" value="-26.5" lower_limit="-30.0" upper_limit="-23.0"/>
                    <measurement group_id="O3" value="-27.8" lower_limit="-31.3" upper_limit="-24.2"/>
                    <measurement group_id="O4" value="-10.3" lower_limit="-13.9" upper_limit="-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment</title>
        <description>Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 (‘normal’, not ill) to 7 (extremely ill).</description>
        <time_frame>6-Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lurasidone 80 mg</title>
            <description>Lurasidone 80 mg tablets taken orally once a day</description>
          </group>
          <group group_id="O2">
            <title>Lurasidone 160 mg</title>
            <description>Lurasidone 160 mg (4 tablets) taken orally once a day</description>
          </group>
          <group group_id="O3">
            <title>Quetiapine XR 600mg</title>
            <description>Quetiapine XR 600 mg (4 tablets) orally taken once a day</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to &gt;= 5%.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome: CGI-S From Baseline to the End of the Double-blind Treatment</title>
          <description>Clinical Global Impression of Severity is a clinician-rated assessment of the subject's current illness state on a 7 point scale, where a higher score is associated with greater illness severity. The scale has a single item measured on a 7 point scale from 1 (‘normal’, not ill) to 7 (extremely ill).</description>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="116"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-1.7" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-1.9" upper_limit="-1.5"/>
                    <measurement group_id="O3" value="-1.7" lower_limit="-1.9" upper_limit="-1.5"/>
                    <measurement group_id="O4" value="-0.9" lower_limit="-1.1" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days post study therapy</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lurasidone 80 mg</title>
          <description>Lurasidone 80 mg tablets taken orally once a day</description>
        </group>
        <group group_id="E2">
          <title>Lurasidone 160 mg</title>
          <description>Lurasidone 160 mg (4 tablets) taken orally once a day</description>
        </group>
        <group group_id="E3">
          <title>Quetiapine XR 600mg</title>
          <description>Quetiapine XR 600 mg (4 tablets) orally taken once a day</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to &gt;= 5%.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia Obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="119" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyschotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Suicidal Behavior</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical Assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Labile Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="119"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Increase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="121"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="121"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="119"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="119"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="119"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="119"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="119"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="125"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="119"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Josephine Cucchiaro, PhD, Executive Director</name_or_title>
      <organization>Sunovion</organization>
      <phone>201-592-2050</phone>
      <email>josephine.cucchiaro@sunovion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

